Recurrent ANCA-associated small vessel vasculitis after transplantation: A pooled analysis  by Nachman, Patrick H. et al.
Kidney International, Vol. 56 (1999), pp. 1544–1550
DIALYSIS – TRANSPLANTATION
Recurrent ANCA-associated small vessel vasculitis after
transplantation: A pooled analysis
PATRICK H. NACHMAN, MA˚RTEN SEGELMARK, KERSTIN WESTMAN, SUSAN L. HOGAN,
KAREN K. SATTERLY, J. CHARLES JENNETTE, and RONALD FALK
Division of Nephrology and Hypertension, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA,
and University of Lund, Lund, Sweden
Recurrent ANCA-associated small vessel vasculitis after trans- small vessel vasculitis (ANCA-SVV) and glomerulone-
plantation: A pooled analysis. phritis, this group of diseases continues to cause end-
Background. Recurrent antineutrophil cytoplasmic anti- stage renal disease in a substantial proportion of patients.body (ANCA)-associated small vessel vasculitis (ANCA-SVV)
As a result, one would anticipate that the number ofafter renal transplantation has been described in case series.
patients with ANCA-SVV and end-stage renal diseaseHowever, general information regarding the frequency, charac-
ter, and predictors of recurrent disease after transplantation is will increase, bringing to the forefront issues pertaining
currently lacking. We considered the rate of relapse, whether to renal transplantation in this patient population.
a positive ANCA at the time of transplantation predicted re- Successful renal transplantation in patients with ANCA-lapse, and whether cyclosporine A prevented recurrent disease.
SVV has been reported in multiple case reports [1–3].Methods. We performed a pooled analysis of published data,
These include patients who were in full remission andadded to the experience at the Universities of North Carolina
(14 patients) and Lund, Sweden (11 patients). To avoid re- with negative ANCA tests, but also patients in remission
porting bias, only case series were included for analysis. Sub- with positive ANCA tests at the time of transplantation
group analysis was performed by disease category (Wegener’s [abstract; Noel, Clin Exp Immunol 93(Suppl 1):43, 1993]granulomatosis, microscopic polyangiitis, or necrotizing cres-
[4–7] and even in patients with evidence of active vasculi-centic glomerulonephritis) and ANCA staining pattern.
tis at the time of transplantation [8].Results. ANCA-SVV recurred in 17.3% of all patients (N 5
127), in 20% of cyclosporine A-treated patients (N 5 85), and Recurrent disease after transplantation has also been
in 25.6% of patients with circulating ANCA at the time of described in several case reports. These recurrences have
transplantation (N 5 39). There was no statistically significant
occurred as early as a few days post-transplantation [9, 10]difference in the relapse rate between patients treated and
and as late as several years post-transplantation [11–16].those not treated with cyclosporine A (P 5 0.45), between
those with and without circulating ANCA at the time of trans- Just as with the initial ANCA-SVV, reported recur-
plant (P 5 0.75), or between patients with Wegener’s granulo- rences after transplantation cover a spectrum of various
matosis and those with microscopic polyangiitis or necrotizing organ involvement in addition to the transplanted kidney
crescentic glomerulonephritis alone (P 5 0.62).
[12, 14, 17].Conclusion. There is a substantial relapse rate in the ANCA-
Although these case reports give an idea of the possi-SVV population. Therapy with cyclosporine A does not protect
against recurrent ANCA-SVV, and the presence of a positive ble outcomes of renal transplantation in patients with
ANCA at the time of transplantation does not preclude trans- ANCA-SVV, they fail to provide general information
plantation. These conclusions must be substantiated with a pro- regarding the frequency and timing of recurrent disease,spective study of renal transplantation in patients with ANCA-
the effect and importance of clinical remission and ofSVV so as to optimize their management.
circulating ANCA prior to transplantation on outcome
and risk of recurrent disease, and the effect of antirejec-
Despite better recognition and improved treatment of tion therapy in general and of cyclosporine A in particu-
anti-neutrophil cytoplasmic antibody ANCA-associated lar in preventing relapses [18].
To date, several case series have reported recurrence
rates ranging from 11 to 50%. These series are, however,Key words: relapse, ANCA, renal transplantation, cyclosporine A,
end-stage renal failure. too small to provide statistically meaningful data. Be-
cause the number of patients with ANCA-SVV who un-Received for publication June 30, 1998
dergo renal transplantation is small in any center, suchand in revised form March 3, 1999
Accepted for publication April 7, 1999 questions are unlikely to be answered by any individual
group. For this reason, we performed a pooled analysis 1999 by the International Society of Nephrology
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of the published data regarding renal transplantation in To evaluate the effects of circulating ANCA, treat-
patients with ANCA-SVV, adding to it reviews of the ment with cyclosporine A, disease category, and ANCA
experiences at the University of North Carolina and the pattern on disease recurrence, continuity adjusted chi-
Glomerular Disease Collaborative Network (GDCN) square and Fisher’s exact tests were performed. A Wil-
and the experience at the University of Lund, Sweden. coxon rank-sum test was used to compare the time on
The aim of this study is to assess the outcome of renal dialysis (continuous variable) between patients who re-
transplantation in patients with ANCA-SVV, the rate lapsed and those who did not. As data for ANCA testing
of relapse of ANCA-SVV post-transplantation, the ef- or immunosuppressive regimen were not always avail-
fect of a positive ANCA on the rate of relapses, and the able, only patients for whom such data were described
effect of cyclosporine A on the rate of relapse. were included in the analysis of each variable.
Definition of relapse
METHODS
A patient was considered to have a relapse if at least
A computerized literature search was performed using one of the following criteria occurred [19, 20]: (a) a rapid
MEDLINE and the following terms: transplantation,
rise in serum creatinine accompanied by an active urine
vasculitis, ANCA, Wegener’s granulomatosis, and micro-
sediment; (b) a renal biopsy demonstrating active necro-scopic polyangiitis. All reports in the English language
sis or crescent formation; (c) hemoptysis, pulmonarywere reviewed, including a review of the cited references.
hemorrhage, or new or expanding nodules without evi-In order to avoid reporting bias, only case series (includ-
dence for infection; (d) active vasculitis of the respiratorying more than one patient) were included for the pooled
or gastrointestinal tracts as demonstrated by endoscopyanalysis. In reviewing these case series, patients in whom
with biopsy; (e) iritis or uveitis; ( f) new mononeuritisthe diagnosis of ANCA-SVV was established retrospec-
multiplex; or (g) necrotizing vasculitis identified by atively were retained in the pooled analysis only when
biopsy in any tissue. The documentation of a rise inANCA-SVV could be documented to be the cause of
ANCA titer was not necessary for the establishment ofrenal failure based on the clinical presentation (for exam-
a relapse. For the pooled analysis, the rate of relapseple, rapidly progressive glomerulonephritis, SVV, hema-
for each study was based on the respective authors’ as-turia, and proteinuria). (For this reason, one patient
sessment, as detailed clinical data were not always avail-whose renal failure was attributable to chronic infection
able for each reported patient.was excluded from analysis in the report by Stegeman
et al [6]). Because of prior literature reviews, care was
taken to count reported patients only once. RESULTS
Data derived from the University of Lund (11 pa-
Experience of the University of North Carolina and
tients), and the University of North Carolina and GDCN
the Glomerular Disease Collaborative Network(14 patients) were added to the data derived from the
Fourteen patients (five females and nine males) fol-literature review. The GDCN is a group of 250 nephrolo-
lowed within the GDCN received a total of 15 trans-gists from 80 private community offices and three medi-
plants. Six patients had microscopic polyangiitis. Fivecal schools, primarily located in North Carolina and the
patients had necrotizing and crescentic glomerulonephri-southeast region of the United States. The pooled analy-
tis alone, and three had Wegener’s granulomatosis. Eightsis was performed by looking at the overall rate of recur-
patients had P-ANCA, and five had C-ANCA. The meanrence of ANCA-SVV, as well as the recurrence rates for
duration on dialysis prior to transplantation was 16patients with a positive ANCA and those treated with
months (range 0 to 48 months). Nine patients receivedcyclosporine A. A subgroup analysis was also performed
grafts from cadaveric donors, and six received grafts frombased on disease category (Wegener’s granulomatosis
living-related donors. The mean age at transplantationvs. microscopic polyangiitis or necrotizing crescentic glo-
was 42 years. The mean time of follow-up post-trans-merulonephritis) and the ANCA staining pattern or anti-
plantation was 44 months (3.6 to 110 months).gen specificity. The specific disease category for each
One of 15 transplants was lost due to early thrombosis.individual patient was as determined by the authors of
For the remaining 14 grafts, 11 patients were treatedeach report, regardless of the year of publication and
with cyclosporine A. At the time of the last visit, ninethe criteria used to establish that diagnosis. As ANCA
patients had a functioning graft, with an average serumtesting has evolved and become more widely accessible
creatinine of 2.0 mg/dl (1.3 to 2.2 mg/dl). No patient hadover the years, the reports of these tests are not uniform
any evidence of recurrent ANCA-SVV or glomerulone-among the various published reports. In an effort to-
phritis. Four patients lost their grafts because of acutewards unification, C-ANCA and anti-PR3 ANCA were
(N 5 1) or chronic rejection (N 5 3), and one patientgrouped together, and so were P-ANCA and anti-MPO
ANCA. suffered from early thrombosis.
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Table 1. Recurrent antineutrophil cytoplasmic antibody-associatedExperience at the University of Lund
small vessel vasculitis (ANCA-SVV) in all reported patients
Eleven patients (2 females and 9 males) received a
Patients Relapse Relapsetotal of 13 transplants (one patient received 3 grafts). Study [Ref] N N %
Seven patients had microscopic polyangiitis and four pa-
Kuross [21] 9 1 11.1
tients had Wegener’s granulomatosis. The four patients Schmitt [8] 11 3 27.3
Haubitz [13] 18 4 22.2with Wegener’s granulomatosis and two patients with
Stegeman [6] 8 2 25microscopic polyangiitis had anti-PR3 antibodies; all the
Grotz [22] 4 2 50.0
other patients had anti-MPO antibodies. Two grafts were Rostaing [5] 8 1 12.5
Frasca [4] 3 0 0.0from living-related donors, and the remaining 11 were from
Nyberg [23] 19 5 26.3cadaveric donors. All patients received cyclosporine A.
Allen [25] 22 2 9.1
The mean age at transplantation was 52.4 years (range UNC 14 0 0.0
Lund 11 2 18.229 to 73 years). The mean time of follow up post-trans-
plantation was 71 months (range 2 to 129 months). Total 127 22 17.3
Two patients with microscopic polyangiitis suffered
recurrent disease at 26 and 36 months post-transplanta-
tion, respectively. In one patient, the relapse was associ-
ated with a loss of graft function. patients, corresponding to a relapse rate of 17.3% (Table 1).
By December 1997, four patients had died 2, 69, 97, The average time to relapse was 30.9 months, ranging
and 122 months post-transplantation. One patient died from 4 to 89 months. Of the 21 patients with recurrent
two months post-transplant secondary to severe pneu- disease for whom clinical information was available, re-
monia and pneumothorax. Six patients had functioning nal involvement occurred in 12 patients, whereas 10 pa-
grafts with a mean creatinine of 1.7 mg/dl (1 to 2.9 mg/dl). tients had relapsing disease affecting extra-renal organs
only. Recurrent vasculitis affecting the upper respiratory
Pooled analysis tract occurred in eight patients, the lungs in six patients,
Twenty-five reports of kidney transplants published the gut in two, the skin in four, the joints in four, and
between the years 1970 and 1997 were identified. Of the eyes in two.
these, only nine were case series, including more than The length of renal replacement therapy prior to trans-
one patient, and were included in the pooled analysis plantation was available on 7 patients who suffered a
[4–6, 8, 21–25]. The two patients reported by van Yper- relapse and 41 patients who did not relapse. The seven
sele de Strihou et al [26] were also included in the review patients with recurrent disease were on dialysis for 7,
18, 18, 21, 38, 144, and 182 months (median 5 21 months).by Kuross, Davin, and Kjellstrand [21]. For this reason,
this article was not included separately in the pooled The median time on dialysis among patients who did not
have a relapse was 17 months (range 0 to 63 months).analysis. Nine of the 15 patients with Wegener’s granulo-
matosis recently reported by Haubitz et al [24] were There was no statistically significant difference in the
distribution of time on dialysis prior to transplantationpreviously included in the report by Schmitt et al [8].
For this reason, only the remaining 11 patients in Schmitt between relapsers and nonrelapsers.
Of the 16 patients with relapse for whom treatmentet al’s report were included in the pooled analysis. A
total of 127 patients was available for analysis of relapse. information was available, 12 received cyclophosphamide,
3 received azathioprine (in addition to cyclosporine AOf the 25 patients with crescentic glomerulonephritis in
the review by Nyberg, only two patients had documented and prednisone), and 1 received high-dose methylpred-
nisolone alone. The treatment of recurrent disease af-positive ANCA tests [23]. Little information was given
about the 23 other patients with crescentic glomerulone- forded long-term remission or remission of therapy in
11 patients. Two relapses were associated with graft loss,phritis. These were therefore not included in the pooled
analysis because of the inability to ascertain from the and one patient was described as having a “remission of
extra-renal vasculitis” but continued to have deteriorat-article that these patients had ANCA-associated pauci-
immune necrotizing glomerulonephritis. Data regarding ing renal function [24]. One patient died as a conse-
quence of relapse.ANCA titers at the time of transplantation were avail-
able on 59 patients, and data regarding immunosuppres- Among patients treated with cyclosporine A (N 5 85),
recurrent disease occurred in 17 patients, correspondingsive treatment were available on 86 patients. Because
identification of patients with relapsing disease was not to a relapse rate of 20% (Table 2). There was no statisti-
cally significant difference in the relapse rate betweenalways complete, the analysis of relapse rate among pa-
tients with circulating ANCA at transplantation could patients treated with cyclosporine A and those not receiv-
ing cyclosporine A (P 5 0.45). Among patients knownbe conducted on only 39 patients.
Recurrent ANCA-SVV disease occurred in 22 of 127 to have circulating ANCA at the time of transplantation
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Table 3. Recurrent (ANCA-SVV) among patients with positiveTable 2. Recurrent (ANCA-SVV) among cyclosporine A
treated patients ANCA at transplantation
Patients Relapse RelapsePatients Relapse Relapse
Study [Ref] N N % Study [Ref] N N %
Kuross [21] NAKuross [21] NA
Schmitt [8] 11 3 27.3 Schmitt [8] NA
Haubitz [13] 6 2 33.3Haubitz [13] 18 4 22.2
Stegeman [6] NA Stegeman [6] 6 2 33.3
Grotz [22] 4 2 50.0Grotz [22] 4 2 50.0
Rostaing [5] 8 1 12.5 Rostaing [5] 8 1 12.5
Frasca [4] 3 0 0Frasca [4] 3 0 0
Nyberg [23] 19 5 26.3 Nyberg [23] 12 3 41.7
Allen [25] NAAllen [25] NA
UNC 11 0 UNC NA
Lund NALund 11 2 18.2
Total 39 10 25.6Total 85 17 20.0
NA, data are not available or incomplete.NA, data are not available or incomplete.
approximately 3% of patients [19]. However, the major-(N 5 39), recurrent disease occurred in 10 patients, cor-
ity of end-stage renal disease is the result of either re-responding to a relapse rate of 25.6% (Table 3). There
peated inflammatory insult to the kidneys or slowly pro-was no statistically significant difference in relapse rate
gressive fibrosis and glomerulosclerosis after an acutebetween patients with circulating ANCA and those with-
flare of necrotizing glomerulonephritis. Because of theseout circulating ANCA at the time of transplant (P 5
phenomena, approximately 20% of patients eventually0.75).
reach end-stage renal disease and the need for renalThe analysis of relapse by disease category revealed
replacement therapy over a period of mean follow-upa rate of relapse of 20.4% among patients with Wegener’s
of 32 months [19, 20, 25].granulomatosis alone compared with 15.7% for patients
Renal transplantation has been recognized as an op-with microscopic polyangiitis or necrotizing crescentic glo-
tion of renal replacement therapy, and reports of success-merulonephritis (Table 4). There was no statistically sig-
ful transplantation in patients with ANCA-associatednificant difference in the rate of relapse between the two
Wegener’s granulomatosis, microscopic polyangiitis, ordisease categories (P 5 0.62). Similarly, patients with C-
necrotizing crescentic glomerulonephritis date back toANCA were no more likely to suffer a relapse than pa-
1972. Because the majority of these reports are limitedtients with P-ANCA (20 vs. 17.2%, respectively, P 5 0.99).
to individual cases or small case series, we pooled data
from published data and our own experience in order
DISCUSSION to address better the important issues related to the
Despite the better recognition and improved treat- long-term outcome of patients with ANCA-SVV after
ment of ANCA-SVV and glomerulonephritis, this group transplantation.
of diseases continues to cause end-stage renal disease Our results show that the overall risk of recurrent
in a substantial proportion of patients. End-stage renal ANCA-SVV is 17%, with an average time from trans-
disease in the setting of ANCA-SVV can be the result of plantation to relapse of 31 months. This rate is somewhat
an acute rapidly progressive glomerulonephritis causing lower than the expected rate reported in nontransplant
severe irreversible glomerular damage or of chronic scar- patients, which ranges from 30 to 45% [19, 20, 28]. It is
ring and slow progression to end-stage renal disease after difficult, however, to compare these average rates of
a period of remission with therapy. In the setting of relapse because the time to relapse is measured differ-
acute renal failure caused by ANCA-associated rapidly ently in each case. In the study of relapse after trans-
progressive glomerulonephritis, the renal outcome of pa- plantation, the time to relapse is measured from the time
tients is in a large part determined by the rapidity with of transplantation, whereas in the nontransplant patient
which a diagnosis is established and immunosuppressive cohorts, the time to relapse is measured from either the
therapy is commenced. As such, the serum creatinine end of treatment (in our study) or an arbitrary time
level at the time treatment is started is the single most after the initiation of treatment or from the beginning
important predictor of renal outcome [27]. In addition, of treatment. Keeping this caveat in mind, this apparent
in our experience, the majority of “treatment resistance” decrease in the rate of relapse probably is attributable
can be attributed to a delay in the initiation of immuno- to the chronic immunosuppressive regimen required to
suppressive therapy [19]. Despite early institution of ap- prevent rejection post-transplantation.
The presence of ANCA at transplantation does notpropriate treatment, treatment resistance still occurs in
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Table 4. Recurrence of ANCA-SVV: Subgroup analysis by disease category and ANCA pattern
WG MPA/GN C ANCA P ANCA
WG relapse MPA/GN relapse C ANCA relapse P ANCA relapse
Total
Study [Ref] patients N
Kuross [21] 9 9 1 0 0 NA NA NA NA
Schmitt [8] 11 11 3 0 0 11 3 0 0
Haubitz [13] 18 15 3 3 1 13 3 3 1
Stegeman [6] 8 2 1 6 1 3 1 5 1
Grotz [22] 4 3 2 1 0 3 2 1 0
Rostaing [5] 8 3 0 5 1 4 0 4 1
Frasca [4] 3 0 0 3 0 0 0 3 0
Nyberg [23] 19 4 1 15 3 NA NA NA NA
Allen [25] 22 NA NA NA NA NA NA NA NA
UNC/GDCN 14 3 0 11 0 5 0 8 0
Lund 11 4 0 7 2 6 0 5 2
Sum 127 54 11 51 8 45 9 29 5
% 20.4 15.7 20.0 17.2
Abbreviations are: WG, Wegener’s granulomatosus; MPA/GN, microscopic polyangiitis or necrotizing crescentic glomerulonephritis alone; NA, data not available
or incomplete.
appear to increase the rate of relapse post-transplanta- ANCA pattern (C-ANCA or P-ANCA) or antigen speci-
ficity (PR3 or MPO). These results are somewhat differ-tion. The data from the pooled analysis are limited not
only by the small number of patients for whom data ent from our patient population with primary ANCA-
SVV. In our cohort of 142 patients treated with cortico-exist, but also by the various techniques in ANCA testing
over the years and center to center differences. This is steroids and cyclophosphamide and followed over a
mean of 26 months, we found that a diagnosis of Wegen-probably more true for the antigen-specific tests for PR3
than MPO, as these tests have become widely available er’s granulomatosis is associated with an increased trend
for relapse as compared with patients with microscopiconly recently, and there continues to be a significant
variation in the results from one testing kit to the other. polyangiitis or glomerulonephritis alone (42% relapse
vs. 30 and 20%, respectively). These different rates ofTherapy with cyclosporine A does not appear to have
a significant protective effect on recurrent ANCA-SVV relapse were not statistically different (P 5 0.63). Con-
versely, in the same patient population, the presence ofover that afforded by other immunosuppressant regimens
(corticosteroids and azathioprine). Assessing the effect of C-ANCA was associated with a statistically significant
increased rate of relapse as compared with P-ANCA (41cyclosporine A depends on comparing patients treated
with cyclosporine A with those not receiving the drug. vs. 21%, P 5 0.04) and a decrease in mean time to relapse
from 18.5 to 9.3 months (abstract; Hogan, Clin Exp Im-With the advent of cyclosporine A in the mid-1980s, the
number of patients not receiving cyclosporine A became munol 112:23, 1998). The different associations of disease
category or ANCA pattern and the risk of relapse be-very small, and any comparison introduces the additional
chronological bias. Such a bias, however, theoretically tween the nontransplant and transplanted patients could
be attributable to the change in the criteria defining eachshould not affect the incidence of relapsing ANCA-SVV.
Whether or not cyclosporine A affords some degree of disease category over the years. Consequently, some pa-
tients described in the literature as having Wegener’sprotection from relapse in nontransplant patients or
whether it has a role in the primary treatment of ANCA- granulomatosis may in fact have microscopic polyangiitis
according to the definitions of the Chapel Hill ConsensusSVV without a concomitant use of corticosteroids or
azathioprine cannot be determined from this study. The Conference [29].
The duration of dialysis prior to transplantation hadlast two years have seen the introduction of mycopheno-
late mofetil to the antirejection armamentarium. Evalua- no effect on the rate of relapse. Among the 48 patients
for whom this information was available, the median timetion of the role of mycophenolate mofetil in the treat-
ment of ANCA-vasculitis is in its infancy, and it remains on dialysis was similar among patients who suffered a
relapse and those who did not. This result does not suggestto be seen if this drug will reduce the incidence of recur-
rent disease post-transplantation. that a delay in transplantation after remission is attained
would decrease the risk of relapse post-transplantation.Our pooled analysis revealed no difference in the rate
of relapse post-transplantation among patients with Weg- As in relapsing disease without transplantation, re-
lapses may vary significantly in organ involvement andener’s granulomatosis as compared with those with mi-
croscopic polyangiitis or necrotizing crescentic glomeru- severity. In our pooled analysis, approximately 60% of
patients had recurrent glomerulonephritis either alonelonephritis alone nor was there a difference based on
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or in addition to other organ involvement, whereas 40% ACKNOWLEDGMENTS
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